484 related articles for article (PubMed ID: 26853848)
1. Acquisition and Presentation of Tumor Antigens by Dendritic Cells.
Bonaccorsi I; Campana S; Morandi B; Ferlazzo G
Crit Rev Immunol; 2015; 35(5):349-64. PubMed ID: 26853848
[TBL] [Abstract][Full Text] [Related]
2. Dendritic Cells and Cancer Immunity.
Gardner A; Ruffell B
Trends Immunol; 2016 Dec; 37(12):855-865. PubMed ID: 27793569
[TBL] [Abstract][Full Text] [Related]
3. Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses.
Silva M; Silva Z; Marques G; Ferro T; Gonçalves M; Monteiro M; van Vliet SJ; Mohr E; Lino AC; Fernandes AR; Lima FA; van Kooyk Y; Matos T; Tadokoro CE; Videira PA
Oncotarget; 2016 Jul; 7(27):41053-41066. PubMed ID: 27203391
[TBL] [Abstract][Full Text] [Related]
4. Human natural killer cells promote cross-presentation of tumor cell-derived antigens by dendritic cells.
Deauvieau F; Ollion V; Doffin AC; Achard C; Fonteneau JF; Verronese E; Durand I; Ghittoni R; Marvel J; Dezutter-Dambuyant C; Walzer T; Vie H; Perrot I; Goutagny N; Caux C; Valladeau-Guilemond J
Int J Cancer; 2015 Mar; 136(5):1085-94. PubMed ID: 25046660
[TBL] [Abstract][Full Text] [Related]
5. Dendritic-tumor cell hybrids induce tumor-specific immune responses more effectively than the simple mixture of dendritic and tumor cells.
Pinho MP; Sundarasetty BS; Bergami-Santos PC; Steponavicius-Cruz K; Ferreira AK; Stripecke R; Barbuto JA
Cytotherapy; 2016 Apr; 18(4):570-80. PubMed ID: 26971685
[TBL] [Abstract][Full Text] [Related]
6. Tumor-Derived Microvesicles Enhance Cross-Processing Ability of Clinical Grade Dendritic Cells.
Dionisi M; De Archangelis C; Battisti F; Rahimi Koshkaki H; Belleudi F; Zizzari IG; Ruscito I; Albano C; Di Filippo A; Torrisi MR; Benedetti Panici P; Napoletano C; Nuti M; Rughetti A
Front Immunol; 2018; 9():2481. PubMed ID: 30455687
[TBL] [Abstract][Full Text] [Related]
7. Engineering anti-cancer nanovaccine based on antigen cross-presentation.
Warrier VU; Makandar AI; Garg M; Sethi G; Kant R; Pal JK; Yuba E; Gupta RK
Biosci Rep; 2019 Oct; 39(10):. PubMed ID: 31652460
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cell biology and its role in tumor immunotherapy.
Wang Y; Xiang Y; Xin VW; Wang XW; Peng XC; Liu XQ; Wang D; Li N; Cheng JT; Lyv YN; Cui SZ; Ma Z; Zhang Q; Xin HW
J Hematol Oncol; 2020 Aug; 13(1):107. PubMed ID: 32746880
[TBL] [Abstract][Full Text] [Related]
9. Exploiting dendritic cells and natural killer T cells in immunotherapy against malignancies.
Fujii S
Trends Immunol; 2008 May; 29(5):242-9. PubMed ID: 18372215
[TBL] [Abstract][Full Text] [Related]
10. Immunological Characterization of Whole Tumour Lysate-Loaded Dendritic Cells for Cancer Immunotherapy.
Rainone V; Martelli C; Ottobrini L; Biasin M; Texido G; Degrassi A; Borelli M; Lucignani G; Trabattoni D; Clerici M
PLoS One; 2016; 11(1):e0146622. PubMed ID: 26795765
[TBL] [Abstract][Full Text] [Related]
11. Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy.
Sánchez-Paulete AR; Teijeira A; Cueto FJ; Garasa S; Pérez-Gracia JL; Sánchez-Arráez A; Sancho D; Melero I
Ann Oncol; 2017 Dec; 28(suppl_12):xii44-xii55. PubMed ID: 28945841
[TBL] [Abstract][Full Text] [Related]
12. Beyond cDC1: Emerging Roles of DC Crosstalk in Cancer Immunity.
Noubade R; Majri-Morrison S; Tarbell KV
Front Immunol; 2019; 10():1014. PubMed ID: 31143179
[TBL] [Abstract][Full Text] [Related]
13. Antigen cross-presentation: extending recent laboratory findings to therapeutic intervention.
Flinsenberg TW; Compeer EB; Boelens JJ; Boes M
Clin Exp Immunol; 2011 Jul; 165(1):8-18. PubMed ID: 21561444
[TBL] [Abstract][Full Text] [Related]
14. Coupled for cross-presentation in tumor immunotherapy.
Pang B; Neefjes J
Sci Transl Med; 2010 Aug; 2(44):44ps40. PubMed ID: 20702855
[TBL] [Abstract][Full Text] [Related]
15. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines.
Dolan BP; Gibbs KD; Ostrand-Rosenberg S
J Immunol; 2006 Feb; 176(3):1447-55. PubMed ID: 16424172
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cell-based cancer immunotherapies.
Fujii S; Takayama T; Asakura M; Aki K; Fujimoto K; Shimizu K
Arch Immunol Ther Exp (Warsz); 2009; 57(3):189-98. PubMed ID: 19479202
[TBL] [Abstract][Full Text] [Related]
17. A novel strategy utilizing ultrasound for antigen delivery in dendritic cell-based cancer immunotherapy.
Suzuki R; Oda Y; Utoguchi N; Namai E; Taira Y; Okada N; Kadowaki N; Kodama T; Tachibana K; Maruyama K
J Control Release; 2009 Feb; 133(3):198-205. PubMed ID: 19000727
[TBL] [Abstract][Full Text] [Related]
18. Eliciting cytotoxic T lymphocytes against human laryngeal cancer-derived antigens: evaluation of dendritic cells pulsed with a heat-treated tumor lysate and other antigen-loading strategies for dendritic-cell-based vaccination.
Wei FQ; Sun W; Wong TS; Gao W; Wen YH; Wei JW; Wei Y; Wen WP
J Exp Clin Cancer Res; 2016 Jan; 35():18. PubMed ID: 26795730
[TBL] [Abstract][Full Text] [Related]
19. Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells.
Groh V; Li YQ; Cioca D; Hunder NN; Wang W; Riddell SR; Yee C; Spies T
Proc Natl Acad Sci U S A; 2005 May; 102(18):6461-6. PubMed ID: 15824323
[TBL] [Abstract][Full Text] [Related]
20. Sustained cross-presentation capacity of murine splenic dendritic cell subsets in vivo.
Ho NI; Camps MGM; de Haas EFE; Ossendorp F
Eur J Immunol; 2018 Jul; 48(7):1164-1173. PubMed ID: 29676785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
